Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
American Society of Clinical Oncology (ASCO)
Online
2022-12-06
DOI
10.1200/jco.22.00830
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
- (2022) Shuyang Yao et al. Scientific Reports
- IGNITE: A phase II signal-seeking trial of adavosertib targeting recurrent high-grade, serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.
- (2022) George Au-Yeung et al. JOURNAL OF CLINICAL ONCOLOGY
- Adavosertib in combination with carboplatin in advanced TP53-mutated platinum-resistant ovarian cancer.
- (2022) Alaa Embaby et al. JOURNAL OF CLINICAL ONCOLOGY
- Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
- (2021) Stephanie Lheureux et al. LANCET
- Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma
- (2021) Joyce F. Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, anti-tumor activity, and biomarker analysis in a phase 1 trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
- (2021) Naoko Takebe et al. CLINICAL CANCER RESEARCH
- 562TiP A phase Ib dose-escalation study of ZN-c3, a WEE1 inhibitor, in combination with chemotherapy in patients with platinum-resistant or -refractory ovarian, peritoneal, or fallopian tube cancer
- (2021) S. Fu et al. ANNALS OF ONCOLOGY
- Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer
- (2021) Peter Q. Huang et al. JOURNAL OF MEDICINAL CHEMISTRY
- WEE1 Inhibitor: Clinical Development
- (2021) Anthony Kong et al. Current Oncology Reports
- Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring
- (2021) Jenny F. Seligmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Glucocorticoid circadian rhythms in immune function
- (2021) Iwona Olejniczak et al. Seminars in Immunopathology
- CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer
- (2020) Justin W. Gorski et al. Diagnostics
- Biomarker‐driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum‐based chemotherapy
- (2020) Sehhoon Park et al. CANCER
- A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer
- (2020) Amit M. Oza et al. CLINICAL CANCER RESEARCH
- Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer
- (2020) Tanya E. Keenan et al. CLINICAL CANCER RESEARCH
- Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer
- (2019) Kyle C. Cuneo et al. JOURNAL OF CLINICAL ONCOLOGY
- Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy
- (2018) Siqing Fu et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints
- (2017) Heng Zhou et al. STATISTICS IN MEDICINE
- Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
- (2016) Suzanne Leijen et al. JOURNAL OF CLINICAL ONCOLOGY
- Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer
- (2014) M. Alsina et al. ANNALS OF ONCOLOGY
- Cyclin E involved in early stage carcinogenesis of esophageal adenocarcinoma by SNP DNA microarray and immunohistochemical studies
- (2014) Zhongren Zhou et al. BMC GASTROENTEROLOGY
- Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma
- (2014) Peter S Harris et al. Molecular Cancer
- Efficient Induction of Apoptosis by Wee1 Kinase Inhibition in Hepatocellular Carcinoma Cells
- (2014) Tomomi Kogiso et al. PLoS One
- Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients – A study of the OVCAD consortium
- (2013) Dietmar Pils et al. EUROPEAN JOURNAL OF CANCER
- WEE1 tyrosine kinase, a novel epigenetic modifier
- (2013) Kiran Mahajan et al. TRENDS IN GENETICS
- Meta-analysis for cyclin E in lung cancer survival
- (2012) Li-nian Huang et al. CLINICA CHIMICA ACTA
- Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption
- (2012) H. Beck et al. MOLECULAR AND CELLULAR BIOLOGY
- Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
- (2012) Marieke Aarts et al. Cancer Discovery
- In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma
- (2010) Shahryar E. Mir et al. CANCER CELL
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now